Sedana Medical

9.96 SEK

-0.60 %

Less than 1K followers

SEDANA

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-0.60 %

+1.74 %

-27.62 %

-17.96 %

-47.80 %

-20.45 %

-49.34 %

-84.94 %

+67.39 %

Sedana Medical operates in the medical technology industry and focuses on the development and manufacture of systems for inhalation anesthesia. The company's products are aimed at healthcare institutions and anesthesiologists. The business is global with a main presence in Europe, North America and Asia. Sedana Medical was founded in 2005 and is headquartered in Danderyd, Sweden.

Market cap

989.4M SEK

Turnover

596.12K SEK

Revenue

178.75M

EBIT %

-28.4 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

12.2

2026

Annual report '25

23.4

2026

Interim report Q1'26

27.5

2026

General meeting '26

All

Webcasts

Press releases

ShowingAll content types

Regulatory press release11/24/2025, 7:00 AM

Sedana Medical reports positive pre-NDA meeting with FDA

Regulatory press release10/24/2025, 5:00 AM

Sedana Medical AB’s Interim report January-September 2025

Regulatory press release10/16/2025, 4:00 PM

Sedana Medical’s Nomination Committee for the 2026 Annual General Meeting

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release10/10/2025, 6:00 AM

Invitation to presentation of Sedana Medical’s interim report for the third quarter 2025

Regulatory press release7/18/2025, 5:00 AM

Sedana Medical AB’s Interim report January-June 2025

Press release7/16/2025, 6:00 AM

Sedana Medical's paediatric study published in The Lancet

Press release7/4/2025, 6:00 AM

Invitation to presentation of Sedana Medical’s interim report for the second quarter 2025

Press release6/10/2025, 6:00 AM

Both of Sedana Medical´s pivotal US studies meet first key secondary endpoint

Regulatory press release5/15/2025, 3:00 PM

Report from Sedana Medical AB’s annual general meeting on 15 May 2025

Regulatory press release5/6/2025, 5:00 AM

Sedana Medical AB’s Interim report January-March 2025

Press release4/25/2025, 7:30 AM

Invitation to presentation of Sedana Medical’s interim report for the first quarter 2025

Press release4/23/2025, 6:00 AM

Sedana Medical Receives FDA Approval for Early Access Program in the U.S.

Regulatory press release4/15/2025, 6:00 AM

Notice of Annual General Meeting in Sedana Medical

Regulatory press release4/10/2025, 3:32 PM

Sedana Medical publishes its Annual Report for 2024

Press release3/19/2025, 10:18 AM

Invitation to investor call related to the SESAR study results

Press release3/18/2025, 10:06 AM

Sedana Medical comments on publication of Investigator Initiated Study results (SESAR)

Press release2/17/2025, 7:33 AM

Redeye: Sedana Medical Q4 - Slightly better than expected

Regulatory press release2/13/2025, 6:00 AM

Sedana Medical AB’s Year-end report 2024

Regulatory press release2/12/2025, 4:30 PM

Sedana Medical announces positive high-level results also for its second pivotal trial in the United States

Regulatory press release2/3/2025, 4:30 PM

Sedana Medical receives an additional year of market protection for Sedaconda® (isoflurane)

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.